The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Rosiglitazone and cardiotoxicity –weighing the evidence
Open accessAbstract
The recently published meta-analysis by Nissen and Wolski,1 which suggested a significant increase in the risk of myocardial infarction associated with treatment with rosiglitazone (Avandia) and an increase of similar magnitude, albeit nonsignificant, in the risk of death from cardiovascular causes, has created a furor in the press and a quandary for physicians and their patients. Given the vagaries of meta-analyses in general and of this meta-analysis in particular — owing to the absence of primary or time-to-event data, as acknowledged both in the article and in the accompanying editorial2 — clinicians have been left uncertain as to whether rosiglitazone . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the pharmacologic strategies, the thiazolidenidiones, also known as PPAR-gamma agonists, are powerful insulin sensitizers effective in lowering insulin resistance [66] and preventing T2D [67], with efficacy similar to lifestyle strategies and greater than metformin [68].”
From Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial (2016) · cites this paper as [67]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Choi, D., Kim, S., Choi, S. H., Ko, Y., Ahn, C. W., Jang, Y., Lim, S.-K., Lee, H., & Soo, B. (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2654 · Cited by 243
Finding New Treatments for Diabetes — How Many, How Fast . . . How Good?
Nathan, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068294 · Cited by 216
Rosiglitazone and Cardiovascular Risk
Psaty, B. M., & Furberg, C. D. (2007) · New England Journal of Medicine · doi:10.1056/nejme078099 · Cited by 179
Home, P. D., Pocock, S., Beck‐Nielsen, H., Gomis, R., Markolf Hanefeld, E., Dargie, H., Michel Komajda, N., Gubb, J., Biswas, N., & Jones, N. P. (2005) · Diabetologia · doi:10.1007/s00125-005-1869-1 · Cited by 149
Rosiglitazone RECORD study: glucose control outcomes at 18 months
Home, P., Jones, N. P., Pocock, S., Beck‐Nielsen, H., Gomis, R., Markolf Hanefeld, E., Michel Komajda, N., Curtis, P. S., & for the RECORD Study Group (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02160.x · Cited by 82
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1056/NEJMoa073394 · DOI · Paper page
Cited by
Sorted by citations
Items 101–127 of 127
Viereck, C., & Boudes, P. F. (2009) · Contemporary Clinical Trials · doi:10.1016/j.cct.2009.03.010 · Cited by 2
Glitazones et insuffisance cardiaque : résultats des études PROactive, ADOPT, DREAM et RECORD
Flines, J. C. D., & Scheen, A. J. (2007) · JMIG · doi:10.53738/revmed.2007.3.122.1876 · Cited by 1
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01536-5 · Cited by 1
Shriya, A. S. K., Pawar, V. B., & Paul, A. A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998305019240702095537 · Cited by 2
Identification of novel scaffolds for Monoamine oxidase B inhibitors.
Odhar, H. A. (2014) · OhioLink ETD Center (Ohio Library and Information Network) · doi:10.13140/rg.2.2.30232.44800 · Cited by 1
Dinneen, S. F. (2008) · Medicine · doi:10.1016/j.mpmed.2007.11.001 · Cited by 2
Lehmann, D. F., & Lohray, B. B. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008319791 · Cited by 1
Comments On the Aace/Ace Statement on Glycemic Control for Patients With Type 2 Diabetes Mellitus
Eledrisi, M. S., Rodbard, H. W., Jellinger, P. S., Palma, M. J. D. C., Hernández, F. J. G., Román, J. S., Mariash, C. N., Shaw, S. J., & Bughi, S. (2010) · Endocrine Practice · doi:10.4158/ep.16.1.130 · Cited by 1
Gysling, E. (2007) · pharma-kritik · doi:10.37667/pk.2006.172 · Cited by 1
Klotz, U. E. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0383-4
Nathan, D. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1257-3
Persistencia del control glucémico en función de los fármacos antidiabéticos orales
González-Clemente, J. M. (2008) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(08)70631-4
[Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
Reboldi, G. (2009) · PubMed
Reviewbias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010)
Typ-2-Diabetes im Licht neuster klinischer Studien
Scherbaum, W. A. (2007) · Der Diabetologe · doi:10.1007/s11428-007-0149-8
Erbe, D. V., & Tobin, J. F. (2008)
Brown, B., & Holt, R. I. G. (2008) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2008.04.02.35
Rosiglitazone: More Data, Continuing Concern
Brett, A. S. (2007) · Journal watch · doi:10.1056/jw200706120000002
McGovern, A. P. (2018) · Surrey Research Insight Open Access (The University of Surrey)
New pharmacological approaches in type 2 diabetes mellitus
Cusi, K. J. (2009) · Dialnet (Universidad de la Rioja) · doi:10.1016/b978-84-8086-683-5.50016-0
Síndrome metabólico post-trasplante hepático en Castilla y León
Pajares, F. G. (2016) · doi:10.35376/10324/39293
Thérapeutique des désordres glycémiques
(2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00007-x
Thérapeutique des désordres glycémiques
(2010) · Elsevier eBooks · doi:10.1016/b978-2-294-70868-8.50007-4
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Current awareness: Pharmacoepidemiology and drug safety
(2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1482
Taşçı, A., Kırkpantur, E. D., Öztürk, T. C., & Turan, C. A. (2024) · doi:10.22541/au.170665281.14718191/v1
Metadata
- Authors
- Nathan, D. M.
- Affiliations
- Harvard University (US)
- Corresponding author
- Nathan, David M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-07-05
- Volume
- 357
- Issue
- 1
- Pages
- 64-66
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2008001887
- Cited by
- 126
- References
- 10
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 1 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 5 · 2015: 6 · 2014: 6 · 2013: 1 · 2012: 2
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- rosiglitazone, cardiotoxicity, myocardial infarction risk, cardiovascular mortality, meta-analysis critique, time-to-event data, thiazolidinediones, type 2 diabetes
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Heart Failure, Humans, Hypoglycemic Agents, Metformin, Sulfonylurea Compounds, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
